NasdaqGS:DNLIBiotechs
Denali’s AVLAYAH Approval Shifts Focus To Valuation And Pipeline Potential
Denali Therapeutics (NasdaqGS:DNLI) received FDA approval for AVLAYAH, its first commercial drug for pediatric Hunter syndrome.
The company reported a strong early launch for AVLAYAH, highlighting initial commercial traction for its brain penetrant platform.
This milestone marks Denali's transition from a development focused biotech to a commercial stage company.
The approval provides an initial test of Denali's approach to delivering therapies across the blood brain barrier for neurological...